The Valley Desk

ArticleJournal of medical economicsPublished

Cost per responder for teclistamab and elranatamab in relapsed or refractory multiple myeloma in the United States

Read the publication ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Article
Venue
Journal of medical economics
Published
Subject terms
Humans; Multiple Myeloma; Antineoplastic Agents; Models, Econometric; Aged; Middle Aged; Cost-Benefit Analysis; United States; Female; Male; Multicenter Studies as Topic; Clinical Trials, Phase I as Topic
PubMed ID
40495704
Added to directory
Source checked

Report a correction or request removal